150969-58-7

Basic information

• Product Name: Benzoic acid, 3-[(trimethylsilyl)ethynyl]-, ethyl ester
• CAS NO: 150969-58-7
• Molecular Formula: C14H18O2Si
• Molecular Weight: 246.381
• Mol File: 150969-58-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-[(trimethylsilyl)ethynyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-[(trimethylsilyl)ethynyl]-, ethyl ester(150969-58-7)
• EPA Substance Registry System: Benzoic acid, 3-[(trimethylsilyl)ethynyl]-, ethyl ester(150969-58-7)

Safety Data

• Hazardous Substances Data: 150969-58-7(Hazardous Substances Data)

Upstream product

• 24398-88-7 ethyl 3-bromobenzoate 
• 1066-54-2 trimethylsilylacetylene 
• 58313-23-8 3-iodobenzoic acid methyl ester 

Downstream Products

• 835595-10-3 3-(1-benzyl-5,6-dichloro-1H-indol-2-yl)benzoic acid 
• 835595-13-6 3-(5,6-dichloro-1H-indol-2-yl)benzoic acid ethyl ester 
• 835595-02-3 3-(5,6-dichloro-1-methylindol-2-yl)benzoic acid 
• 835595-05-6 3-(5-chloro-1-benzofuran-2-yl)benzoic acid 
• 10601-99-7 3-ethynylbenzoic acid 
• 1262847-43-7 3-{3-[4-(4-methylpiperazin-1-yl)phenyl]isoxazol-5-yl}benzoic acid 
• 1262845-65-7 N-isopropyl-3-{3-[4-(4-methylpiperazin-1-yl)phenyl]isoxazol-5-yl}benzamide 
• 1262845-64-6 3-{3-[4-(4-methylpiperazin-1-yl)phenyl]isoxazol-5-yl}benzoic acid ethyl ester 
• 29203-58-5 4-bromo-N-hydroxybenzenecarboximidoyl chloride 
• 25062-46-8 4-bromobenzaldehyde oxime 
• 178742-95-5 ethyl 3-(ethynyl)benzoate 

Relevant articles and documents

Cobalt-Catalyzed Hydroalkynylation of Vinylaziridines

Transition metal-catalyzed hydroalkynylation reactions are efficient transformations allowing the straightforward formation of functionalized alkynes. Therein, we disclose the cobalt-catalyzed hydroalkynylation of vinylaziridines giving rise to both linea

Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction

The transcription factor Nrf2 regulates the expression of a large network of cytoprotective and metabolic enzymes and proteins. Compounds that directly and reversibly inhibit the interaction between Nrf2 and its main negative regulator Keap1 are potential pharmacological agents for a range of disease types including neurodegenerative conditions and cancer. We describe the development of a series of 1,4-diphenyl-1,2,3-triazole compounds that inhibit the Nrf2-Keap1 protein-protein interaction (PPI) in vitro and in live cells and up-regulate the expression of Nrf2-dependent gene products.

NOVEL COMPOUNDS

Compounds of the formula (I) are disclosed which are large conductance calcium activated potassium channel openers (BK channels openers) and are useful in the treatment of urinary tract disorders: (I), or a pharmaceutically acceptable salt thereof.